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Abstract: Identiﬁ  cation of novel molecular targets is critical in development of new and 
efﬁ  cient cancer therapies. Kinases are one of the most common drug targets with a potential 
for cancer therapy. Cell cycle progression is regulated by a number of kinases, some of which 
are being developed to treat cancer. Cdc7 is a serine-threonine kinase originally discovered in 
budding yeast, which has been shown to be necessary to initiate the S phase. Inhibition of Cdc7 
in cancer cells retards the progression of the S phase, accumulates DNA damage, and induces 
p53-independent cell death, but the same treatment in normal cells does not signiﬁ  cantly affect 
viability. Low-molecular-weight compounds that inhibit Cdc7 kinase with an IC50 of less than 
10 nM have been identiﬁ  ed, and shown to be effective in the inhibition of tumor growth in animal 
models. Thus Cdc7 kinase can be recognized as a novel molecular target for cancer therapy.
Keywords: Cdc7 kinase, cell cycle, replication fork, genome stability, DNA damages, 
ATP-binding pocket, kinase inhibitor
Introduction
Recent studies on the molecular basis of various diseases have revealed that the 
deregulation of protein phosphorylation reactions by kinases is clearly associated with 
many disease states, especially cancer (Noble et al 2004). Thus modulating aberrant 
kinase activities in cancer cells may form an effective cancer therapy, with fewer side 
effects than traditional cytotoxic drugs. A number of kinases have been studied as 
potential targets for cancer therapy (Collins and Workman 2006). Kinases regulating 
the cell cycle, including Cdk (cyclin-dependent kinase), Aurora kinases, and Chk1 
kinase, have also been the focus of many studies on cancer-treating agents (Fischer 
et al 2003; Collins and Garrett, 2005; Warner et al 2006; de Carcer et al 2007) in part 
because these cell cycle-regulating kinases are overproduced in cancer cells.
Cdc7 is a conserved serine-threonine kinase, which was originally identiﬁ  ed 
in budding yeast and shown to be required for the initiation of DNA replication 
(Hartwell 1971; Patterson et al 1986; Sclafani 2000). Subsequent studies showed that 
Cdc7 is required not only for initiation but also for stable maintenance of replication 
forks (Snaith et al 2000; Takeda et al 2001; Fung et al 2002; Matsumoto et al 2005; 
Sommariva et al 2005). This brief article summarizes the latest knowledge on the 
functions of Cdc7 kinase, and current efforts on the design of a drug based on this 
interesting molecule.
Roles of Cdc7 in initiation of DNA replication 
and checkpoint regulation
Initial characterization of a budding yeast cdc7 temperature-sensitive mutant indicated 
that Cdc7 is required to initiate DNA synthesis. Cdc7 is a serine-threonine kinase, which 
belongs to a unique group in the kinase family (Figure 1). Cdc7 forms a complex with Dbf4 
(Johnston and Thomas 1982; Kitada et al 1992; Jackson et al 1993), an activation subunit. Drug Design, Development and Therapy 2008:2 256
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Figure 1 Homology analyses of human Cdc7 kinase. A)The human kinome tree. Kinase family members were classiﬁ  ed into the following eight subgroups on the basis of their 
primary structures: CAMK (calcium/calmodulin-dependent kinase group), TK (tyrosine kinase group), RGC (receptor guanylyl cyclase group), TKL (tyrosine kinase-like group), STE 
(sterile phenotype kinase group), CK1 (cell kinase 1/casein kinase 1 group), AGC (protein kinases A, G and C group), CMGC (cyclin-dependent-kinase [CDK], mitogen-activated-
kinase [MAPK], glycogen-synthase-kinase [GSK] and CDK-like kinase group). B) A phylogenetic tree of Cdc7 and some human protein kinases which are most similar to Cdc7.Drug Design, Development and Therapy 2008:2 257
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Both cdc7 and dbf4 are temperature-sensitive mutants 
of budding yeast and arrest with 1C DNA content at a 
non-permissive temperature, suggesting a defect in the initiation 
of DNA replication. In 1995, the ﬁ  rst functional homologue of 
Cdc7 was identiﬁ  ed in ﬁ  ssion yeast (Masai et al 1995). After 
this discovery, conserved presence of both Cdc7 and Dbf4 
subunits was demonstrated across the species (Masai et al 1999; 
Masai and Arai 2002).
Cdc7 is essential for viability in yeasts. Knockout of Cdc7 
genes in mice leads to early embryo death; the mutant embryos 
die between E3.5 and 6.5. Conditional knockout of Cdc7 
genes in mouse embryonic stem cells resulted in the arrest of 
DNA synthesis, accumulation of nuclear DNA damage, and 
eventual p53-dependent cell death (Kim et al 2002). These 
results suggest that Cdc7 kinase has critical roles in DNA 
replication, which may be conserved across species.
The conserved targets for Cdc7 kinase are MCM subunits, 
and phosphorylation of the N-terminal non-conserved tails 
of MCM2, 4, and 6 proteins has been shown to facilitate the 
association of Cdc45 and other replisome factors with pre-
replicative complex (pre-RC) (Masai et al 2000, 2006; Sheu 
and Stillman 2006). This step is crucial for the generation of 
active and efﬁ  cient replication fork structures (Figure 2).
The replication fork is under continuous attack both 
internally and externally, clearly indicated by the fact that a 
recombinational repair system is essential for the viability 
of vertebrate cells (Sonoda et al 1998). Proper processing 
of stalled replication forks and the resumption of DNA 
replication are essential for completion of the entire genome 
duplication within the given S phase. Cellular responses to 
stalled replication forks are regulated by checkpoint reac-
tions. A defect in checkpoint regulation poses serious threats 
to the stable maintenance of the genome. Indeed mutations in 
checkpoint regulators have been demonstrated to be respon-
sible for various tumors or diseases (Michelson and Weinert 
2000; D’Andrea and Grompe 2003; Narek and Lukas 2003). 
Checkpoint responses are composed of two phases; the medi-
ator and effector phases. The former is involved in activating 
checkpoint kinases, while the latter is involved in executing 
the checkpoint effects (Niida and Nakanishi 2006). Accumu-
lating evidence indicates the critical roles of Cdc7 kinase in 
both phases of DNA replication checkpoint responses. Chk1 
is activated in response to replication fork arrest, and Cdc7 
appears to be required for this activation (Kim et al 2008). 
Claspin is a mediator of checkpoint responses and is hyper-
phosphorylated in response to stalled replication forks. Cdc7 
is required for this step (Kim et al 2008). In ﬁ  ssion yeast, 
the activation of Cds1, a checkpoint effector kinase, and 
hyperphosphorylation of Mrc1 (a ﬁ  ssion yeast counterpart 
of Claspin) in response to fork arrest, depend on Hsk1, the 
ﬁ  ssion yeast homologue of Cdc7 kinase (Takeda et al 2001; 
Shimmoto et al unpublished data). Claspin/Mrc1 is efﬁ  ciently 
phosphorylated by Cdc7/Hsk1 in vitro, suggesting that pos-
sibly Cdc7 directly regulates the checkpoint activation (Kim 
et al 2008; Kakusho et al unpublished data). The requirement 
of Cdc7 for continuous activation of the Rad53 checkpoint 
kinase in response to HU has also been reported in budding 
yeast (Ogi et al 2008). On the other hand, the role of Cdc7 
in the effector phase was suggested by the fact that Cdc7 is 
inactivated in Xenopus egg extracts in response to etopside, 
a DNA-damaging agent introducing single-stranded nicks 
(Costanzo et al 2003). Cdc7 was also shown to be down-
regulated by etopside in human cells (Dierov et al 2004). 
Evidence showing that the fork block inhibits Cdc7 kinase 
was also reported in budding yeast (Weinreich and Stillman 
1999). These results strongly suggest the dual roles of Cdc7 
kinase in the mediator and effector phases of checkpoint 
responses. However researchers report that Cdc7 activity is 
unaltered by replication fork blocks in human cells (Tenca 
et al 2007). Furthermore, we cannot rule out the possibility 
that defects in the DNA replication fork caused by Cdc7 
depletion contributes to the apparent defect in checkpoint 
activation. Whatever the mechanisms are, loss of Cdc7 func-
tions in actively proliferating cells causes replication fork 
arrest which results in DNA damage, and simultaneously 
leads to defective checkpoint activation.
Structure and activation of Cdc7 
kinase complex
Unique features of Cdc7 include the presence of two or three 
amino acid segments which interrupt the kinase domains 
at conserved locations (Figure 3). Although the functional 
signiﬁ  cance of these kinase insert sequences has not been 
deﬁ  ned, association of nuclear localization and nuclear export 
activities with the second and third inserts, respectively, was 
reported for human Cdc7 (Kim et al 2007). Cdc7 associates 
with chromatin during the S through G2 phase, and dissoci-
ates from chromatin during the M phase (Masai et al 2006) 
when it is phosphorylated, presumably by Cdc2 kinase. 
Kinase activity may not be regulated by Cdk-mediated 
phosphorylation, since Escherichia coli-generated Cdc7 
kinase is highly active and the activity is not affected by Cdk 
(Kakusho et al unpublished data).
Cdc7 kinase is generally active only when it associ-
ates with an activation subunit (Johstone et al 1999; Masai 
et al 1999, 2000; Masai and Arai 2002). The Dbf4-like Drug Design, Development and Therapy 2008:2 258
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Figure 2 Scheme of initiation of eukaryotic DNA replication and action of Cdc7 kinase. Eukaryotic DNA replication is initiated by binding of ORC (origin recognition 
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activation subunits share three conserved motifs, namely 
Dbf4-motif-N, -M and -C (Masai and Arai 2000). The 
Dbf4-motif-N, a BRCT-like motif, is not essential for kinase 
activation, nor for cell viability in yeasts, although mutations 
in motif-N result in sensitivity to replication fork blockages 
induced by HU and other agents in yeasts (Ogino et al 2001; 
Varrin et al 2005; Gabrielse et al 2006). The Dbf4-motif-M 
(proline-rich novel motif) or motif-C (C2H2-type zinc-ﬁ  nger 
motif) is capable of binding to Cdc7 on its own, but the maxi-
mum activation, and viability in ﬁ  ssion yeast cells through 
meiosis, require the presence of both motifs connected by 
a non-conserved linker segment (Ogino et al 2001). On the 
other hand, survival through mitosis in ﬁ  ssion yeast can be 
maintained only by the motif-M, albeit with reduced growth 
rate, whereas motif-C is required for resistance to the alkylat-
ing reagent, methyl methanesulfonate (Fung et al 2002). In 
mammalian cells, in addition to motif-M and motif-C, motif-N 
is also required for viability (Yamashita et al 2005).
Members of kinases structurally close to Cdc7 include 
casein kinase (Figure 1B). Although the precise substrate 
recognition code is not known for Cdc7 kinase, it is clear 
that Cdc7 is an acidophylic kinase, preferring the presence 
of acidic residues near the phosphorylation site. This feature 
is shared by casein kinase. It was reported recently that 
positively charged polymers such as polyamines strongly 
stimulate Cdc7 kinase activity, whereas the negatively 
charged polymers such as nucleic acids severely inhibit 
Cdc7 kinase activity (Kakusho et al 2008). These characters 
of Cdc7 are also shared by casein kinase (Hathaway and 
Traugh 1984), reinforcing the structural similarity between 
Cdc7 and casein kinase.
Downregulation of Cdc7 causes cell 
death preferentially in cancer cells
siRNA-mediated downregulation of Cdc7 expression 
in various cancer cells induced retardation of S phase 
progression, followed by accumulation of nuclear damage, 
presumably induced by a stalled replication fork which 
was not properly stabilized and collapsed (Montagnoli et al 
2004; Yoshizaw-Sugata et al 2005; Im and Lee 2008; Kim 
et al 2008). Cells then undergo chromosome fragmentation 
and die, which occurs in both p53-positive and -minus cells, 
indicating that cell death is p53-independent (Montagnoli 
et al 2004). Cells appear to die mostly by entering aberrant 
mitosis. In contrast, normal ﬁ  broblast cells do not die in 
signiﬁ  cant quantities under the same conditions. S phase 
cells slow down DNA synthesis and some DNA damage 
appears in nuclei, but is eventually repaired. Cells in 
other cell cycles may be arrested in the G1 phase in a 
p53-dependent manner (Montagnoli et al 2004; Ishii et al 
unpublished data).
The precise mechanisms of cancer-speciﬁ  c cell death 
are not clear. Depletion of Cdc7 would cause defects in ﬁ  ring 
of the replication origins as well as acute destabilization 
of replication forks which would eventually collapse. 
Furthermore, checkpoint defects may trigger uncoupling 
of the M phase with the S phase. Therefore we suggest 
that the combined effect of replication fork arrest and deﬁ  -
cient checkpoint responses might augment cell death by 
inducing aberrant cell cycle progression. Whereas normal 
cells could cope with these situations through backup 
checkpoint mechanisms, cancer cells, in which checkpoint 
mechanisms are very often partially abrogated, would suffer 
from aberrant M phase progression caused by checkpoint 
abrogation. Researchers reported recently that ATR-induced 
activation of p38 MAP kinase causes caspase activation in 
Cdc7-depleted cancer cells (Im and Lee 2008).
Structural features of ATP-binding 
pocket of Cdc7 kinase
A ligand ATP binds to the ATP-binding pocket through 
hydrogen bonds with the hinge region connecting the N- and 
C-terminal lobes of the kinase catalytic domain (Figure 4). 
Most kinase inhibitors reported so far also bind to this hinge 
region with additional interactions with two hydrophobic 
regions (sites B and E in Figure 4) adjacent to the ATP-binding 
pocket. The hydrophobic region I (E in Figure 4) is commonly 
referred to as the selectivity pocket, because the size of a single 
residue in the interior of this region, termed the gatekeeper, has 
been shown to be a critical determinant of inhibitor sensitivity 
(Cherry and Williams 2004; Vieth et al 2004). Based on our 
in-house human kinome database, approximately 90 kinases 
possess a small threonine gatekeeper, and 190 kinases have a 
large methionine residue. According to a homology model of 
Cdc7 we built in-house, the large gatekeeper residue (Met134) 
appears to make the entrance to the hydrophobic region I 
very narrow, and the back pocket of this site is occupied by 
residues Val120 and Ile132 (Figure 5). The central portion 
of the adenine-binding region is formed by a hydrophobic 
sandwich with two residues, Met118 and Ile64, suggesting 
that a ﬂ  at hydrophobic core may be preferred as an inhibitor 
scaffold. In the same region, typical hydrogen bonds may 
be formed with the backbone of the hinge region. Two ionic 
residues, Lys90 and Asp196, could provide opportunities for 
the design of potent inhibitors with appropriate substituent 
targeting these residues.Drug Design, Development and Therapy 2008:2 260
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Emerging Cdc7 kinase inhibitors
Only a handful of Cdc7 kinase inhibitors have been reported 
so far (Figures 6 and 7). A series of pyrrolopyridinone 
compounds with potent activity against Cdc7 has been 
reported by Nerviano Medical Sciences (Montagnoli et al 
2008a; Vanotti et al 2008). PHA-767491 (#1) was identiﬁ  ed 
from high throughput screening (HTS) and characterized 
as an ATP-competitive inhibitor of Cdc7 (IC50 = 10 nM). 
This compound recapitulates the most relevant molecular 
phenotypes that are expected from Cdc7 inhibition 
(Montagnoli et al 2008a). It inhibited Cdc7-directed 
phosphorylation of a substrate protein (Mcm2) as well as 
DNA synthesis, and induced cell death in multiple cancer cell 
lines, but did not affect the viability of normal cells (NHDF; 
normal human dermal ﬁ  broblasts). Treatment of NHDF with 
PHA-767491 indicates that Cdc7 inhibition may prevent 
the activation of replication origins but does not trigger a 
sustained DNA damage response.
Subsequent optimization of this scaffold led to 
3-aminopyrimidine analog (compound #2; IC50 = 7 nM). 
The Structure Activity Relationship (SAR) study suggested 
that the aminopyrimidine group probably interacts with the 
hinge. Although the compound #2 showed antiproliferative 
activity against the A-2780 ovarian cancer cell line, it 
exhibited poor membrane permeability in the PAMPA 
assay which would cause low oral absorption. Further 
optimization led to (S)-2-(2-aminopyrimidiny-4-yl)-7-(2-
ﬂ  uoroethyl)-1,5,6,7-tetrahydropyrrolo[3,2-c]pyridinone 
(compound #3; Menichincheri et al 2007). Compound #3, 
which had an IC50 value of 2 nM against Cdc7 with greater 
than 60-fold selectivity over other kinases, showed excellent 
inhibition of cell proliferation in various tumor lines with 
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Figure 5 A homology model of Cdc7 kinase. A) Mapping of important residues within the ATP-binding pocket of Cdc7 kinase based on a homology model.   The dotted circle 
area marks the hydrophobic area (adenine-binding region) formed by a hydrophobic sandwich with two residues Met118 and Ile64. Possible hydrogen bonds between an 
inhibitor and the ATP-binding site of Cdc7 are indicated by the arrows. B) A model of staurosporine bound to the ATP-binding site of Cdc7 shown by Van der Waals surfaces. 
The negatively and positively charged regions are shown in pink and blue, respectively, on the Van der Waals surfaces. Oxygen and nitrogen are shown in red and blue, respectively. 
The carbon atoms in the ligand (staurosporine) and in the protein are shown in white and green, respectively.
B A
NH
O
HN
O
O
N
H
O H
N
S
Lys90 H2N
Met118
S
Leu184
Val 195
Val72
Ile64
hinge region
gatekeeper (Met134)
Asp196
O
ODrug Design, Development and Therapy 2008:2 261
Drug design with Cdc7 kinase
submicromolar IC50 values. In addition, compound #3 was 
found to be effective in an A2780 cell line mouse xenograft 
model, when administered twice daily at an oral dose of 
60 mg/kg for 10 days. In the DMBA-induced mammary 
carcinoma rat model, compound #3 was also active at a 
dose of 20 mg/kg.
The Nerviano group also examined other possible 
modiﬁ  cations to the pyrrolopyridinone scaffold and disclosed 
novel pyrrole compounds, such as compound #4 (Vanotti et al 
2007). A clinical candidate, NMS-354, which is derived from 
the same chemical class as compound #4, was reported as 
an orally available Cdc7 inhibitor (IC50 = 3 nM; Montagnoli 
et al 2008b). NMS-354 is potent in blocking proliferation 
and inducing apoptosis in a broad panel of 120 cancer cell 
lines with IC50 values in the submicromolar range. In vivo, 
NMS-354 has a broad range of activities when administered 
singly (20 mg/kg) in different xenograft tumor models 
(ovarian, colon, mammary, leukemia) and also in a rat mam-
mary carcinogenic-induced tumor model (DMBA) with tumor 
growth inhibition of more than 80% without toxic effects. 
NMS-354 is currently under preclinical evaluation.
Researchers at Hoffmann-La Roche explored a series of 
tricyclic Cdc7 inhibitors and identiﬁ  ed potent and selective 
compounds (Zhao et al 2005). A pyridothienopyrimidine 
was identified from HTS and subsequent structural 
optimization resulted in the discovery of compound #5 
which is a potent Cdc7 inhibitor with Ki of 2 nM (Figure 7). 
Compound #5 showed high selectivity against a panel of 
11 kinases. However, no further progress on this compound 
has been reported.
Recently, Novartis reported a series of 4-indazolylpyrimidin-
2(1H)-one as potent Cdc7 inhibitors (Shafer et al 2007, 
2008). Compound #6 was identiﬁ  ed as a potent inhibitor 
of Cdc7 with an IC50 = 5 nM (Figure 7). They predict the 
binding mode of this series of compounds on the basis of 
the co-crystal structure of the parent compound, phenol 
pyrimidin-2(1H)-one, with PIM-1 kinase. The structure 
shows that the phenol and pyrimidinone are coplanar, and 
this ﬂ  at shape is expected to ﬁ  t well with the Cdc7 ATP-
binding site as described in the previous section. Although 
the details of the interactions may be different between 
PIM-1 and Cdc7, the structure suggested that the NH group 
in the indazole ring is likely to bind to the hinge region of 
Cdc7. Unfortunately, this series of compounds exhibits low 
membrane permeability as well as metabolic liability, and, 
in fact, showed weak cellular activity.
Various Cdc7 kinase inhibitors have also been disclosed 
in the patent literatures recently (Figure 7). Thienopyrazoles 
have been claimed as Cdc7 inhibitors by Pharmacia 
(now Pfizer) (Tonani et al 2004). In this application, 
compound #7 was described as possessing Cdc7 kinase-
inhibiting activity with IC50  1000 nM. However, no kinase 
selectivity data were presented.
The 2-pyrimidyl-5-amidothiophenes were identiﬁ  ed as 
an AKT inhibitor by Chiron (now Novartis Vaccines and 
Diagnostics; Lin et al 2005). The patent application for this 
compound series claims that these analogs also have inhibi-
tory activities against Cdc7 as exempliﬁ  ed by compound #8. 
However, no activity data were presented.
A series of imidazolones was recently disclosed in a patent 
application by Sanoﬁ  -Aventis (Leroy et al 2008). They claim 
that the members of this series, as represented in compound 
#9, have inhibitory activities against Cdc7. However, no data 
were presented to substantiate these claims.
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Figure 6 Cdc7 kinase inhibitors reported by Nerviano Medical Sciences. 1, PHA-767491 (IC50 = 10 nM), 2, 3-aminopyrimidine analog (IC50 = 7 nM), 3, (S)-2-(2-aminopyrimidiny-
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Figure 7 Structures of other Cdc7 inhibitors. 5,  Tricyclic Cdc7 inhibitor (Roche); 6, indazolylpyrimidin-2(1H)-one inhibitor (Novartis); 7, thienopyrazole-base inhibitor (Pﬁ  zer); 
8, 2-pyrimidyl-5-amidothiophene analog (Novartis Vaccines and Diagnostics); 9, imidazolone-based inhibitor (Sanoﬁ  -Aventis).
Conclusions and perspectives
Although Cdc7 is essential for the viability of eukaryotic 
cells, its inhibition or depletion leads to cell death speciﬁ  cally 
in cancer cells. This is caused by acute genomic instability 
induced by the combined effects of replication fork arrest, 
its destabilization and aberrant M phase due to checkpoint 
defect. Cancer cells are generally associated with defects 
in checkpoint response pathways, and thus exhibit greater 
sensitivity to S phase perturbation than normal cells. 
Thus Cdc7 has emerged as a potentially effective target for 
cancer therapy.
Potent compounds capable of inhibiting Cdc7 kinase 
with nM IC50 were recently reported, and were shown to 
be effective in reducing tumor growth in mouse xenograft 
models. Only a few patent applications have been disclosed 
so far for Cdc7 kinase inhibitors, and it is not yet possible 
to determine which compounds will prove most promis-
ing, because detailed evaluation of the compounds at the 
cellular level or in animal models has not been conducted 
for most of these compounds. Nevertheless, because of the 
unique nature of its structure and action, inhibitors of Cdc7 
kinase would be promising candidates for novel classes of 
cancer drugs.
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